Monica Andres, DPM
Foot & Ankle Surgery · Miami, FLNPI 1427001692
Payments from drug & device makers
Across 14 payments — averaging $1075.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$15K
- Smith+Nephew$86
- KCI USA, Inc.$83
- Paratek Pharmaceuticals, Inc.$50
- Stimwave Technologies Incorporated$25
- IBSA Pharma Inc.$17
What the payments were for
- Food & beverage$2612%
- Other$14,80098%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 1 | $14,800 |
| Smith+Nephew | 4 | $86 |
| KCI USA, Inc. | 4 | $83 |
| Paratek Pharmaceuticals, Inc. | 3 | $50 |
| Stimwave Technologies Incorporated | 1 | $25 |
| IBSA Pharma Inc. | 1 | $17 |
How this compares
$15,061 in reported general payments places this provider in the 80th percentile of 850 foot & ankle surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Potassium | 128 | $467,665 |
| Diflorasone Diacetate | 121 | $106,863 |
| JubliaEfinaconazole | 88 | $86,832 |
| Ketoconazole | 135 | $49,550 |
| Ciclopirox | 285 | $46,750 |
| Tavaborole | 47 | $39,129 |
| Diclofenac Epolamine | 29 | $13,530 |
| MupirocinMupirocin Calcium | 26 | $12,846 |
| SantylCollagenase Clostridium Hist. | 16 | $6,586 |
| Diclofenac Sodium | 78 | $4,953 |
| Clotrimazole | 53 | $1,933 |
| Lidocaine | 18 | $1,849 |
| Ammonium Lactate | 77 | $1,508 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 36 | $1,183 |
| CiclopiroxCiclopirox Olamine | 21 | $698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $86 | $6,58616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 850 foot & ankle surgery providers in Florida.
Other foot & ankle surgery in Miami
- Imaze DavisMiami$147K
- Thomas ZwickMiami$108K
- Bamidele OluponaMiami$68K
- Thomas SangiovanniCoral Gables$2.1M
- Shayne JensenPanama City$1.3M
- Thomas RoukisOrlando$1.1M
- Craig BreslauerStuart$971K
- Bradley LammWest Palm Beach$938K
- Amber ShaneOrlando$830K
- Jonathan BlumKissimmee$814K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.